Is CO or MRAI more profitable?

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Company Net Margins Return on Equity Return on Assets Global Cord Blood N/A N/A N/A Marpai -85.70% N/A -100.23%

Do analysts recommend CO or BNTC?

Benitec Biopharma has a consensus target price of $27.00, indicating a potential upside of 118.09%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Benitec Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56

Is CO or BNTC more profitable?

Global Cord Blood's return on equity of 0.00% beat Benitec Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Global Cord Blood N/A N/A N/A Benitec Biopharma N/A -34.82% -34.11%

Do analysts recommend STTK or CO?

Shattuck Labs presently has a consensus target price of $11.00, indicating a potential upside of 71.50%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe Shattuck Labs is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80 Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is STTK or CO more profitable?

Global Cord Blood's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Global Cord Blood N/A N/A N/A

Do analysts prefer CO or SOPH?

SOPHiA GENETICS has a consensus target price of $7.50, suggesting a potential upside of 26.26%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Global Cord Blood. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Cord Blood 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SOPHiA GENETICS 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Global Cord Blood (CO) Competitors

$1.00 0.00 (0.00%)

As of 06/26/2026

Compare

CO vs. MRAI, BNTC, STTK, SOPH, and CYH

Should you buy Global Cord Blood stock or one of its competitors? MarketBeat compares Global Cord Blood with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Global Cord Blood include Marpai (MRAI), Benitec Biopharma (BNTC), Shattuck Labs (STTK), SOPHiA GENETICS (SOPH), and Community Health Systems (CYH).

How does Global Cord Blood compare to Marpai?

Global Cord Blood (NYSE:CO) and Marpai (NASDAQ:MRAI) are both small-cap miscellaneous health & allied services, not elsewhere classified industry companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Global Cord Blood has higher revenue and earnings than Marpai. Marpai is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.10	$79.04M	$0.64	1.56
Marpai	$34.87M	0.59	-$28.75M	-$0.87	N/A

In the previous week, Global Cord Blood's average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Global Cord Blood	Neutral
Marpai	Neutral

49.8% of Marpai shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Global Cord Blood has a net margin of 0.00% compared to Marpai's net margin of -85.70%.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

Global Cord Blood has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Marpai has a beta of 4.94, indicating that its share price is 394% more volatile than the broader market.

Summary

Global Cord Blood beats Marpai on 6 of the 10 factors compared between the two stocks.

How does Global Cord Blood compare to Benitec Biopharma?

Global Cord Blood (NYSE:CO) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Global Cord Blood's return on equity of 0.00% beat Benitec Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Benitec Biopharma	N/A	-34.82%	-34.11%

Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Benitec Biopharma has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Benitec Biopharma has a consensus target price of $27.00, indicating a potential upside of 118.09%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Benitec Biopharma is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

52.2% of Benitec Biopharma shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by insiders. Comparatively, 4.8% of Benitec Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Global Cord Blood has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.10	$79.04M	$0.64	1.56
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A

In the previous week, Benitec Biopharma had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 1 mentions for Benitec Biopharma and 0 mentions for Global Cord Blood. Benitec Biopharma's average media sentiment score of 1.87 beat Global Cord Blood's score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
Benitec Biopharma	Very Positive

Summary

Benitec Biopharma beats Global Cord Blood on 8 of the 14 factors compared between the two stocks.

How does Global Cord Blood compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

In the previous week, Shattuck Labs had 3 more articles in the media than Global Cord Blood. MarketBeat recorded 3 mentions for Shattuck Labs and 0 mentions for Global Cord Blood. Shattuck Labs' average media sentiment score of 0.29 beat Global Cord Blood's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Shattuck Labs	Neutral
Global Cord Blood	Neutral

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market.

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Shattuck Labs presently has a consensus target price of $11.00, indicating a potential upside of 71.50%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe Shattuck Labs is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Global Cord Blood has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	491.83	-$48.81M	-$0.63	N/A
Global Cord Blood	$1.24B	0.10	$79.04M	$0.64	1.56

Global Cord Blood's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Global Cord Blood	N/A	N/A	N/A

Summary

Shattuck Labs beats Global Cord Blood on 9 of the 15 factors compared between the two stocks.

How does Global Cord Blood compare to SOPHiA GENETICS?

Global Cord Blood (NYSE:CO) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

In the previous week, SOPHiA GENETICS had 11 more articles in the media than Global Cord Blood. MarketBeat recorded 11 mentions for SOPHiA GENETICS and 0 mentions for Global Cord Blood. SOPHiA GENETICS's average media sentiment score of 0.27 beat Global Cord Blood's score of 0.00 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.

Company	Overall Sentiment
Global Cord Blood	Neutral
SOPHiA GENETICS	Neutral

SOPHiA GENETICS has a consensus target price of $7.50, suggesting a potential upside of 26.26%. Given SOPHiA GENETICS's stronger consensus rating and higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

31.6% of SOPHiA GENETICS shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Global Cord Blood has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, SOPHiA GENETICS has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Global Cord Blood has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -44.48%. Global Cord Blood's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%

Global Cord Blood has higher revenue and earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$1.24B	0.10	$79.04M	$0.64	1.56
SOPHiA GENETICS	$77.27M	6.45	-$79M	-$0.52	N/A

Summary

SOPHiA GENETICS beats Global Cord Blood on 9 of the 16 factors compared between the two stocks.

How does Global Cord Blood compare to Community Health Systems?

Community Health Systems (NYSE:CYH) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, Community Health Systems had 2 more articles in the media than Global Cord Blood. MarketBeat recorded 2 mentions for Community Health Systems and 0 mentions for Global Cord Blood. Community Health Systems' average media sentiment score of 0.25 beat Global Cord Blood's score of 0.00 indicating that Community Health Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Community Health Systems	Neutral
Global Cord Blood	Neutral

Community Health Systems has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Global Cord Blood has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market.

Community Health Systems currently has a consensus price target of $3.28, suggesting a potential downside of 0.35%. Given Community Health Systems' stronger consensus rating and higher probable upside, equities research analysts clearly believe Community Health Systems is more favorable than Global Cord Blood.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Community Health Systems	2 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.88
Global Cord Blood	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Community Health Systems has higher revenue and earnings than Global Cord Blood. Community Health Systems is trading at a lower price-to-earnings ratio than Global Cord Blood, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Community Health Systems	$12.29B	0.04	$509M	$3.43	0.96
Global Cord Blood	$1.24B	0.10	$79.04M	$0.64	1.56

Community Health Systems has a net margin of 3.78% compared to Global Cord Blood's net margin of 0.00%. Global Cord Blood's return on equity of 0.00% beat Community Health Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Community Health Systems	3.78%	-7.62%	0.73%
Global Cord Blood	N/A	N/A	N/A

85.0% of Community Health Systems shares are owned by institutional investors. 11.1% of Community Health Systems shares are owned by insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Community Health Systems beats Global Cord Blood on 13 of the 16 factors compared between the two stocks.

Get Global Cord Blood News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CO vs. The Competition

Export

Metric	Global Cord Blood	health & allied services, not elsewhere classified Industry	Medical Sector	NYSE Exchange
Market Cap	$121.55M	$87.88M	$6.82B	$23.32B
Dividend Yield	N/A	N/A	2.67%	4.08%
P/E Ratio	1.56	0.78	25.82	31.37
Price / Sales	0.10	0.34	551.75	20.18
Price / Cash	4.19	4.19	29.09	18.60
Price / Book	0.16	0.16	10.90	4.76
Net Income	$79.04M	$25.15M	$3.58B	$1.07B
7 Day Performance	5.15%	7.21%	2.42%	1.03%
1 Month Performance	N/A	2.80%	0.14%	0.36%
1 Year Performance	N/A	-36.51%	35.46%	24.81%

Global Cord Blood Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CO Global Cord Blood	N/A	$1.00 flat	N/A	N/A	$121.55M	$1.24B	1.56	1,202
MRAI Marpai	N/A	$0.64 0.0%	N/A	-47.0%	$17.06M	$34.87M	N/A	150
BNTC Benitec Biopharma	1.9675 of 5 stars	$13.35 +3.6%	$27.00 +102.2%	+9.0%	$457.89M	$80K	N/A	20
STTK Shattuck Labs	4.111 of 5 stars	$5.92 +9.8%	$11.00 +85.8%	+654.4%	$454.33M	$1M	N/A	100	Short Interest Increase
SOPH SOPHiA GENETICS	3.4864 of 5 stars	$5.41 +3.4%	$7.50 +38.6%	+86.1%	$453.87M	$81.18M	N/A	520	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Global Cord Blood (CO) Competitors

CO vs. MRAI, BNTC, STTK, SOPH, and CYH

How does Global Cord Blood compare to Marpai?

Summary

How does Global Cord Blood compare to Benitec Biopharma?

Summary

How does Global Cord Blood compare to Shattuck Labs?

Summary

How does Global Cord Blood compare to SOPHiA GENETICS?

Summary

How does Global Cord Blood compare to Community Health Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Global Cord Blood (CO) Competitors

CO vs. MRAI, BNTC, STTK, SOPH, and CYH

How does Global Cord Blood compare to Marpai?

Which has preferable earnings and valuation, CO or MRAI?

Does the media favor CO or MRAI?

Do insiders and institutionals hold more shares of CO or MRAI?

Is CO or MRAI more profitable?

Which has more risk and volatility, CO or MRAI?

Summary

How does Global Cord Blood compare to Benitec Biopharma?

Is CO or BNTC more profitable?

Which has more risk and volatility, CO or BNTC?

Do analysts recommend CO or BNTC?

Do institutionals & insiders have more ownership in CO or BNTC?

Which has stronger valuation & earnings, CO or BNTC?

Does the media prefer CO or BNTC?

Summary

How does Global Cord Blood compare to Shattuck Labs?

Does the media favor STTK or CO?

Which has more risk and volatility, STTK or CO?

Do institutionals & insiders believe in STTK or CO?

Do analysts recommend STTK or CO?

Which has preferable earnings and valuation, STTK or CO?

Is STTK or CO more profitable?

Summary

How does Global Cord Blood compare to SOPHiA GENETICS?

Does the media favor CO or SOPH?

Do analysts prefer CO or SOPH?

Do institutionals & insiders hold more shares of CO or SOPH?

Which has more volatility & risk, CO or SOPH?

Is CO or SOPH more profitable?

Which has preferable valuation and earnings, CO or SOPH?

Summary

How does Global Cord Blood compare to Community Health Systems?

Does the media prefer CYH or CO?

Which has more volatility and risk, CYH or CO?

Do analysts recommend CYH or CO?

Which has better earnings & valuation, CYH or CO?

Is CYH or CO more profitable?

Do insiders & institutionals hold more shares of CYH or CO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CO vs. The Competition

Global Cord Blood Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools